Q1 Earnings Estimate for aTyr Pharma Issued By HC Wainwright

aTyr Pharma, Inc. (NASDAQ:ATYR) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of aTyr Pharma in a research report issued on Friday, March 6th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.15) per share for the quarter. The consensus estimate for aTyr Pharma’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04.

ATYR has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a report on Friday. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.67.

aTyr Pharma Stock Performance

Shares of ATYR stock opened at $0.82 on Monday. The stock’s fifty day moving average is $0.84 and its 200-day moving average is $1.39. The stock has a market capitalization of $80.79 million, a PE ratio of -1.04 and a beta of 0.55. aTyr Pharma has a 52 week low of $0.64 and a 52 week high of $7.29.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Profund Advisors LLC acquired a new position in shares of aTyr Pharma during the third quarter valued at $27,000. California State Teachers Retirement System acquired a new stake in aTyr Pharma in the second quarter worth about $28,000. ADAR1 Capital Management LLC raised its holdings in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after purchasing an additional 13,385 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in aTyr Pharma during the 4th quarter valued at about $41,000. Finally, Ameritas Investment Partners Inc. acquired a new position in aTyr Pharma during the 2nd quarter valued at about $45,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.